Education: Faculty of Pharmacy, Medical University, Lublin, Poland; Master’s degree (highest honor), Department of Biochemistry; Doctoral thesis in pharmacology (highest honor), Department of Pharmacodynamics; Habilitation thesis in Pharmacology (highest honor), idem; since 2010–Full Professor degree, now: the Head of the Chair and Department of Pharmacology and Pharmacodynamics; since 2012 – Vice-Dean of the Faculty of Pharmacy with Medical Analitics Division, Medical University of Lublin, Poland. 1991-2009: Recipient of seven fellowships of French and Polish Government; in total 5 years of training and regular post in Paris; 9 Erasmus Plus training. Author of 230 papers, tutor of 10 doctoral thesis, number of citations: 1500; citation index=22. Review of papers for international and polish journals: 233; of scientific grants: 117, principle investigator of polish and international (”Polonium”) grants and UE projects. Member of 15 Editorial Board of open-access journals. Member of the Polish Academy of Science Commissions. Languages: Polish: native; French: fluently; English, Russian. Research subjects: psychopharmacology, pharmacotherapy, experimental pharmacology. The central effects of psychoactive drugs and natural products (including locomotor sensitization, cross-sensitization, place conditioning and withdrawal syndrome, chronic mild unpredictable stress), anxiety, memory and learning, depression, nociception, Parkinson and Alzheimer disease, psychosis, measured in behavioral paradigms. The common molecular mechanisms shared by addiction and memory processes; the neurobiological mechanisms of drug dependence (the influence of endocannabinoid system, calcium homeostasis and kinases/phosphatases balance) and further strategies for its pharmacotherapy.
My research activity and scientific production primarily deal with the pathobiology of several respiratory disorders such as asthma, COPD, interstitial pulmonary diseases and lung cancer, and also regard the molecular mechanisms underlying the therapeutic actions of the main drugs used for their treatments. In particular, my current studies are focusing on the role of “mitogen-activated protein kinases” in the signal transduction pathways activated by cytokines, growth factors and oxidative stress in primary cultures of human pulmonary endothelial cells, bronchial epithelial cells, lung cancer cell lines, and pulmonary fibroblasts. A major research interest concerns the activation and inhibition of these enzymes in cell death and proliferation, as well as in development and pharmacological modulation of lung inflammation and remodelling. I am also particularly interested in the recent advances referring to the biological therapies of asthma, with special regard to anti-IgE treatment, with whom I am familiar since ten years ago. I have been actively involved in many basic studies and clinical trials, among which the most relevant include: (i) “Role of signal transduction pathways activated by oxidative stress or proliferative stimuli in the development and progression of lung cancer: possible diagnostic, prognostic, therapeutic and preventive implications”, financed by a grant of the Italian Ministry for University and Scientific Research (n. 2003061034 – years 2003-2004); (ii) International study “CIGE025A2425”, financed by Novartis and aimed to evaluate the clinical effects in severe, uncontrolled allergic asthma, of the humanized anti-IgE monoclonal antibody omalizumab (years 2005-2006); (iii) A Pan-European open randomised study comparing the efficacy and cost-effectiveness of Symbicort Maintenance and Reliever Therapy – Symbicort SMART – using a maintenance dose of Symbicort 160/4.5 ?g, 1 or 2 inhalations twice daily in the treatment of persistent asthma – EUROSMART (D5890L00022 – years 2007-2008). I conducted clinical research according to GCP. My scientific production comprehensively includes over 100 book chapters, reviews and original articles published in both national and international, peer-reviewed journals.
Dr. Gurevich got his PhD in Bioorganic Chemistry at the Shemyakin Institute in Moscow. He studied structure and function of arrestin proteins since he joined the lab of Dr. Benovic as a post-doc in 1991. Dr. Gurevich’s studies revealed why arrestins prefer active phosphorylated GPCRs and how they sense receptor-attached phosphates. His lab constructed phosphorylation-independent arrestin mutants and tested their ability to compensate for the defects of GPCR phosphorylation. His lab elucidated the structural basis of arrestin preference for particular GPCRs and constructed the first non-visual arrestins with high receptor specificity. In collaboration with different crystallographers Dr. Gurevich’s lab solved the structures of all four vertebrate arrestins in basal conformation and the structure of the arrestin-rhodopsin complex.
Arrestins Structure-function, G protein-coupled receptors, Signal transduction, Desensitization Trafficking
Dayue Darrel Duan, M.D., Ph.D., FAHA, is a Professor of Pharmacology and Principle Investigator of the Laboratory of Cardiac and Vascular Phenomics in the Center for Molecular Medicine at the School of Medicine University of Nevada in Reno (UNR), Nevada. Following the completion of his Ph.D. training with Dr. Stanley Nattel in Montreal Heart Institute and McGill University in 1996, Dr. Duan joined the lab of Dr. Joseph R. Hume, a world-leader in cardiovascular ion channels and electrophysiology, with a Canadian MRC postdoctoral fellowship. Dr. Duan became a faculty of UNR as a Research Assistant Professor in the Department of Physiology and Cell Biology in 1998 and rose to an Associate Professor rank in 1999. Dr. Duan was appointed Associate Professor in 2001, tenured Associate Professor in 2005 and Professor in 2009 in the Department of Pharmacology at UNR. In his 30 years of research and study in cardiovascular field Dr. Duan discovered several anion channels in the heart and has made significant original contributions to the study of biophysics, physiology, pharmacology, and molecular biology of ion channels in the cardiovascular system. His current research focuses on the phenomics of ion channels in the cardiac and vascular systems. The Duan laboratory has been being continuously supported by research grants from NIH, American Heart Association (AHA), and American Diabetes Association. His laboratory has established several animal models for cardiac diseases and hypertension and has the capacity to study the genome-phenome relationship and molecular mechanisms for cardio- and cerebrovascular disease at multiple levels ranging from whole animal to molecular levels. He delivered over 100 invited lectures worldwide. He is currently a member of the Editorial Board of numerous journals, Associate Editor of Acta Pharmacologica Sinica and Editor-in-Chief of Journal of Clinical & Experimental Cardiology.
The long-term goal of Dr. Duan's Laboratory of Cardiac and Vascular Phenomics is to determine the molecular mechanisms for the functional role of ion channels in the cardiac and vascular diseases. Ion channels play significant roles in cardiac electrical activity and contractile function. In addition, ion channels are important regulators of acidification of intracellular organelles, cell volume, proliferation, differentiation, and apoptosis. Ion channels interact with many partners and function as an integrated "ion channel module" or "channel protein complex". Under pathological conditions "ion channel modules" often undergo remodeling and provide substrates for cardiovascular disease such as cardiac rhythm and contraction disorders and hypertension. Therefore, the systematical study of ion channels has important significance in the translational medicine for the prevention and treatment of cardiac and vascular diseases. Chloride (Cl-) channels in the cardiovascular system, including the PKA- and PKC-activated CFTR Cl- channels, the volume-regulated outwardly rectifying ClC-3 and inwardly rectifying ClC-2 Cl- channels, the Ca2+-activated TMEM16 (Bestrophin and CLAC) Cl- channels, represent new targets for therapeutic agents against heart diseases. To gain mechanistic insights into the functional role of these ion channels in the context of health and disease the Duan laboratory has successfully established several animal models for cardiac diseases and hypertension and has the capacity to study the phenome-genome-proteome relationship and molecular mechanisms for cardiovascular disease at multiple levels of the whole-animal, the isolated organ, the tissue, the cell, and the molecule. The technology platforms used in the Duan laboratory include patch-clamp, molecular biology, genetics, genomics, proteomics, conditional systems for gene targeting and addition, isolated heart perfusion system, echocardiography, and radiotelemetry system.
Assistant Professor, Department of Pharmacology, Faculty of Pharmacy, University Complutense of Madrid (Spain). Member of the Research Group “Pharmacology of Natural Products”. I obtained my European PhD in Pharmacy in 2012 (Extraordinary Doctoral Prize). I had worked for 3 years in the Spanish Agency of Medicines and Medical Devices (AEMPS). Expertise in the study of natural products from medicinal plants and lichens as neuroprotective agents, based on their antioxidant properties, against different models of oxidative stress in cell lines of the nervous system (neurons and astrocytes). Author of many scientific publications (25 in indexed journals, 4 in non-indexed journals and 9 chapters of books) as well as communications in national and international congresses. I have participated as researcher in four National funded projects and research stays at prestigious international centers (King’s College of London and Neuroscience Center in Coimbra). Teaching experience at all levels of higher education in Pharmacology, Toxicology and Pharmacognosy subjects as well as experience in Educational Innovative Projects.
Expertise in the study of natural products from medicinal plants and lichens as neuroprotective agents, based on their antioxidant properties, against different models of oxidative stress in cell lines of the nervous system (neurons and astrocytes)